Migfilin promotes migration and invasion in glioma by driving EGFR and MMP-2 signalings： A positive feedback loop regulation

Glioma is the most common type of primary brain tumors in the central nervous system（CNS）. Migfilin occurs in human glioma and enhances cellular motility via the epidermal growth factor receptor（EGFR）pathway. However, the underlying molecular mechanism is not fully understood. In this study, we foun...

Full description

Saved in:
Bibliographic Details
Published inJournal of genetics and genomics Vol. 44; no. 12; pp. 557 - 565
Main Authors Ou, Yunwei, Wu, Qingnan, Wu, Chuanyue, Liu, Xuefeng, Song, Yongmei, Zhan, Qimin
Format Journal Article
LanguageEnglish
Published China Elsevier Ltd 20.12.2017
Subjects
EGFR
Glioma
Migfilin
MMP-2
Motility
Motility
Glioma
MMP-2
MMPs
PLC-γ
STAT3
Migfilin
CNS
TIMPs
EGFR
ECM
Online AccessGet full text

Cover

More Information
Summary:Glioma is the most common type of primary brain tumors in the central nervous system（CNS）. Migfilin occurs in human glioma and enhances cellular motility via the epidermal growth factor receptor（EGFR）pathway. However, the underlying molecular mechanism is not fully understood. In this study, we found that Migfilin promoted matrix metalloproteinase-2（MMP-2） activity, and restrained the expression of tissue inhibitor of metalloproteinase 2（TIMP2）, which is an MMP-2 inhibitor. Functional and structural studies showed that the LIM1 domain of Migfilin was required for Migfilin-mediated TIMP2 expression inhibition and MMP-2 activity, and was also necessary in promoting cell motility. Furthermore, Migfilininduced EGFR phosphorylation was greatly reduced by MMP-2 inhibitor（GM6001） or si RNA, while Migfilin-induced MMP-2 activation was also blocked by the EGFR inhibitor（AG1478） or si RNA. MMP-2 and EGFR inhibitors and their si RNAs can block Migfilin-induced migration and invasion, respectively.These results demonstrated that EGFR and MMP-2 signalings may form a positive feedback loop to enhance Migfilin-induced migration and invasion. Finally, we detected that the expression of Migfilin,EGFR phosphorylation（Tyr1173） and MMP-2 activity had a positive correlation in the clinical glioma sample. Taken together, these results suggest that Migfilin is a critical regulator in cellular motility by driving the EGFR-MMP-2 feedback loop, and may be considered as a potential therapeutic target in glioma.
Bibliography:Glioma;Migfilin;MMP-2;EGFR;Motility
Glioma is the most common type of primary brain tumors in the central nervous system（CNS）. Migfilin occurs in human glioma and enhances cellular motility via the epidermal growth factor receptor（EGFR）pathway. However, the underlying molecular mechanism is not fully understood. In this study, we found that Migfilin promoted matrix metalloproteinase-2（MMP-2） activity, and restrained the expression of tissue inhibitor of metalloproteinase 2（TIMP2）, which is an MMP-2 inhibitor. Functional and structural studies showed that the LIM1 domain of Migfilin was required for Migfilin-mediated TIMP2 expression inhibition and MMP-2 activity, and was also necessary in promoting cell motility. Furthermore, Migfilininduced EGFR phosphorylation was greatly reduced by MMP-2 inhibitor（GM6001） or si RNA, while Migfilin-induced MMP-2 activation was also blocked by the EGFR inhibitor（AG1478） or si RNA. MMP-2 and EGFR inhibitors and their si RNAs can block Migfilin-induced migration and invasion, respectively.These results demonstrated that EGFR and MMP-2 signalings may form a positive feedback loop to enhance Migfilin-induced migration and invasion. Finally, we detected that the expression of Migfilin,EGFR phosphorylation（Tyr1173） and MMP-2 activity had a positive correlation in the clinical glioma sample. Taken together, these results suggest that Migfilin is a critical regulator in cellular motility by driving the EGFR-MMP-2 feedback loop, and may be considered as a potential therapeutic target in glioma.
11-5450/R
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1673-8527
DOI:10.1016/j.jgg.2017.09.008